155 related articles for article (PubMed ID: 8678706)
1. The Physicians' Desk Reference. Problems and possible improvements.
Cohen JS; Insel PA
Arch Intern Med; 1996 Jul; 156(13):1375-80. PubMed ID: 8678706
[TBL] [Abstract][Full Text] [Related]
2. Editorial: limitations of the physicians' desk reference 2007.
Mindel JS; Teich SA; Teich CM; Beam P
Surv Ophthalmol; 2008; 53(1):82-4. PubMed ID: 18191659
[No Abstract] [Full Text] [Related]
3. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
4. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
[TBL] [Abstract][Full Text] [Related]
5. Risk management strategies in the Physicians' Desk Reference product labels for pregnancy category X drugs.
Uhl K; Kennedy DL; Kweder SL
Drug Saf; 2002; 25(12):885-92. PubMed ID: 12241129
[TBL] [Abstract][Full Text] [Related]
6. Incorrect or unsubstantiated indications listed for selected antimicrobials in the Physicians' Desk Reference.
Rybak MJ; Gleckman R
Am J Hosp Pharm; 1979 Jun; 36(6):738. PubMed ID: 463882
[No Abstract] [Full Text] [Related]
7. Sulfite content of drug products.
Dalton-Bunnow MF
Am J Hosp Pharm; 1985 Oct; 42(10):2196-201. PubMed ID: 4061462
[TBL] [Abstract][Full Text] [Related]
8. The diminishing value of the Physicians' Desk Reference and drug package inserts as a medical and legal standard of medical usage of pharmaceutical drugs.
Burkhart CG
J Drugs Dermatol; 2005; 4(4):414-5. PubMed ID: 16004013
[No Abstract] [Full Text] [Related]
9. Physicians' perceptions and uses of commercial drug information sources: an examination of pharmaceutical marketing to physicians.
Spiller LD; Wymer WW
Health Mark Q; 2001; 19(1):91-106. PubMed ID: 11727295
[TBL] [Abstract][Full Text] [Related]
10. Higher than Physician's Desk Reference (US) doses on atypical antipsychotics.
Goodnick PJ
Expert Opin Drug Saf; 2005 Jul; 4(4):653-68. PubMed ID: 16011445
[TBL] [Abstract][Full Text] [Related]
11. What is prescription labeling communicating to doctors about hepatotoxic drugs? A study of FDA approved product labeling.
Willy ME; Li Z
Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):201-6. PubMed ID: 15255086
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
[TBL] [Abstract][Full Text] [Related]
13. Providing drug information to health professionals and consumers: role and responsibility of the pharmaceutical manufacturer.
Boyland JI
Hosp Pharm; 1983 Apr; 18(4):211-3, 216. PubMed ID: 10260207
[TBL] [Abstract][Full Text] [Related]
14. Setting the record straight on PDR criticisms.
Mehta M
Postgrad Med; 2000 Jan; 107(1):22. PubMed ID: 10649658
[No Abstract] [Full Text] [Related]
15. A population-based study of the prevalence and influence of gifts to radiation oncologists from pharmaceutical companies and medical equipment manufacturers.
Halperin EC; Hutchison P; Barrier RC
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1477-83. PubMed ID: 15275735
[TBL] [Abstract][Full Text] [Related]
16. 'Off-label' prescribing, the Physician's Desk Reference and the court.
Spector RA; Marquez E
J La State Med Soc; 2011; 163(5):276-80. PubMed ID: 22272550
[TBL] [Abstract][Full Text] [Related]
17. Prescription drug products; patient package insert requirements--Food and Drug Administration. Final rule.
Fed Regist; 1981 Jan; 46(1):28-30. PubMed ID: 10324121
[TBL] [Abstract][Full Text] [Related]
18. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
Watson KT; Barash PG
Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852
[TBL] [Abstract][Full Text] [Related]
19. FDA publishes conflict of interest rules for clinical trials. Food and Drug Administration.
James JS
AIDS Treat News; 1998 Mar; (No 290):8. PubMed ID: 11365123
[TBL] [Abstract][Full Text] [Related]
20. Discrepant antihypertensive dose recommendations.
Milic M; Ziegler MG
Clin Exp Hypertens; 2006 Feb; 28(2):171-80. PubMed ID: 16546842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
